ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2025
Mean disease alleviation as a comprehensive metric for evaluating continuous positive airway pressure therapy in obstructive sleep apnea: establishing reference values and clinical significance.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of under-mattress sensor and CPAP data for home monitoring in obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2026Article
- Beyond the apnea-hypopnea index: a call to action for a multidimensional evaluation in obstructive sleep apnea.Frontiers in sleep · 2026Article
- Sleep Medicine-What's in a Name?Journal of sleep research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
STUDY
objectivesObstructive sleep apnea poses significant health risks, warranting effective treatment strategies. Continuous positive airway pressure therapy is widely used, but assessing treatment effectiveness remains complex. This study aimed to establish reference values for mean disease alleviation (MDA) in a large cohort treated with continuous positive airway pressure.
methodsData from the Apnea Positive Pressure Long-term Efficacy Study were analyzed. A total of 352 participants underwent 6 months of continuous positive airway pressure therapy, with adherence and efficacy monitored objectively. MDA, calculated as the product of treatment efficacy and percentage adherence, was assessed. Age and sex differences in MDA and its association with sleepiness (Epworth Sleepiness Scale scores > 10) were evaluated using logistic regression and linear regression models.
resultsThe mean MDA in the 352 participants at 6 months was 53.85% ± 27.22%. Older participants demonstrated higher adherence and MDA compared to younger participants (58.2% ± 27.8% vs 51.1% ± 27.4%,
conclusionsMDA serves as a valuable metric for evaluating obstructive sleep apnea therapy outcomes, integrating both adherence and treatment efficacy. MDA ≥ 40% was associated with clinically meaningful improvements in sleepiness. Embracing MDA as a benchmark for obstructive sleep apnea therapy evaluation holds promise for optimizing personalized and effective obstructive sleep apnea management. CITATION: Budhiraja R, Batool-Anwar S, Quan SF. Mean disease alleviation as a comprehensive metric for evaluating continuous positive airway pressure therapy in obstructive sleep apnea: establishing reference values and clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.